Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2707]

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial...

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

Treating patients with multiple myeloma in the real world

Dr Ajai Chari and Prof Roman Hájek

Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )

ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany

ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with...

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant...

Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal

MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in breast cancer ( Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal )

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA

$Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma ( Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA )$

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

Background of the KEYLYNK-007 trial for advanced solid tumours

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Background of the KEYLYNK-007 trial for advanced solid tumours ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in...

Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib ( Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA )

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase...

Prof Jorge Cortes - Augusta University, Augusta, USA

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia ( Prof Jorge Cortes - Augusta University, Augusta, USA )

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute...

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myeloid leukaemia ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory...

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

$AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory multiple myeloma ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )$

More from ecancer